Stoke Therapeutics Inc
NASDAQ:STOK

Watchlist Manager
Stoke Therapeutics Inc Logo
Stoke Therapeutics Inc
NASDAQ:STOK
Watchlist
Price: 22.85 USD -0.22% Market Closed
Market Cap: 1.3B USD

Wall Street
Price Targets

STOK Price Targets Summary
Stoke Therapeutics Inc

Wall Street analysts forecast STOK stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for STOK is 24.71 USD with a low forecast of 15.15 USD and a high forecast of 36.75 USD.

Lowest
Price Target
15.15 USD
34% Downside
Average
Price Target
24.71 USD
8% Upside
Highest
Price Target
36.75 USD
61% Upside
Stoke Therapeutics Inc Competitors:
Price Targets
TLX
Telix Pharmaceuticals Ltd
72% Upside
MIRM
Mirum Pharmaceuticals Inc
10% Upside
ANVS
Annovis Bio Inc
505% Upside
AUPH
Aurinia Pharmaceuticals Inc
9% Downside
XOMA
XOMA Corp
91% Upside
STTK
Shattuck Labs Inc
4% Downside
PRAX
Praxis Precision Medicines Inc
113% Upside
ALEC
Alector Inc
23% Upside

Revenue
Forecast

Revenue Estimate
Stoke Therapeutics Inc

The compound annual growth rate of Stoke Therapeutics Inc's revenue for the next 3 years is 8%.

N/A
Past Growth
8%
Estimated Growth
Estimates Accuracy
5%
Average Beat

Operating Income
Forecast

Operating Income Estimate
Stoke Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Net Income
Forecast

Net Income Estimate
Stoke Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-33%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is STOK's stock price target?
Price Target
24.71 USD

According to Wall Street analysts, the average 1-year price target for STOK is 24.71 USD with a low forecast of 15.15 USD and a high forecast of 36.75 USD.

What is Stoke Therapeutics Inc's Revenue forecast?
Projected CAGR
8%

The compound annual growth rate of Stoke Therapeutics Inc's revenue for the next 3 years is 8%.

Back to Top